Login / Signup

Implementing the time-to-event continual reassessment method in the presence of partial orders in a phase I head and neck cancer trial.

Amit PatelKristian BrockDaniel SladeClaire GauntAnthony KongHisham MehannaLucinda BillinghamPiers Gaunt
Published in: BMC medical research methodology (2024)
ADePT-DDR was added to the European Clinical Trials Database (EudraCT number: 2020-001034-35) on 2020-08-07.
Keyphrases
  • clinical trial
  • phase ii
  • phase iii
  • study protocol
  • open label
  • quality improvement
  • double blind
  • adverse drug